IPM Take
ALS does not give regulators the luxury of comfortable timelines.
Patients are losing movement, breathing, speech and time while the evidence system debates what counts as enough. Clene’s CNM-Au8 programme is now pushing that debate directly into the accelerated-approval pathway, using neurofilament light response as a central part of the case.
That is important. It is also dangerous if the line between biomarker response and proven clinical benefit becomes too soft.
Urgency should accelerate evidence. It should not make evidence less honest.
Executive Summary
Clene announced new analyses examining outcomes among CNM-Au8-treated ALS patients whose neurofilament light chain, or NfL, levels declined or stabilized. The company said these analyses will be included in its planned New Drug Application seeking accelerated approval.
The analyses are intended to respond to FDA questions raised during a March 2026 Type C meeting. Clene reported that survival benefit and functional benefit appeared concentrated among participants with NfL biomarker response, including measures involving survival, ALSFRS-R and slow vital capacity.
CNM-Au8 is an investigational oral gold nanocrystal suspension designed to support cellular energy metabolism and reduce oxidative stress. Prior CNM-Au8 evidence includes Phase 2 ALS studies and expanded-access data, but no Phase 3 confirmatory survival trial has yet established definitive clinical efficacy.
The planned NDA will test a critical regulatory question: whether ALS-specific biomarker evidence can support accelerated approval while survival and function data serve as supportive or confirmatory evidence.
Why it matters
- Patients / advocates: ALS families need regulatory urgency, but they also need clarity on what is known, what is inferred and what still has to be proved.
- Clinicians: NfL is a meaningful disease biomarker, but clinical decisions depend on whether biomarker response reliably predicts preserved function and survival.
- Regulators: Accelerated approval in ALS may increasingly turn on biomarkers. That makes validation, transparency and post-approval confirmation essential.
- Researchers / academia: The CNM-Au8 case could shape how future ALS programmes link biomarker movement to patient benefit.
ALS is the disease that punishes delay most brutally.
Every month can mean less speech, less movement, less breathing capacity, less independence. That is why the regulatory system is under pressure to move faster. It should be under pressure.
But moving faster does not mean pretending uncertainty has disappeared.
Clene’s new CNM-Au8 analyses sharpen one of the biggest questions in ALS development: can neurofilament light response become strong enough to support accelerated approval? NfL is not a random biomarker. It reflects neuronal injury and has become increasingly important in ALS research and development.
The company’s argument is that patients whose NfL declined or stabilized on CNM-Au8 also showed better survival and functional patterns. If robust, that connection would matter. It could help identify a treatment effect earlier than waiting for large mortality datasets.
But regulators must treat correlation with discipline.
The risk is not that biomarkers enter ALS approval. They should. The risk is that a biomarker becomes a regulatory shortcut before its relationship to patient benefit is secure enough to carry that burden.
Patients do not need a slower system. They need a system that can move fast and still tell the truth.
For CNM-Au8, the next fight is not only scientific. It is institutional. FDA will have to decide how much weight a biomarker-response story can bear in a disease where waiting for perfect evidence can itself become an ethical failure.
